BRCA1 and cancer: With the exception of four cases, all others were previously investigated for BRCA1 and BRCA2 pathogenic variants, and were negative for pathogenic/likely pathogenic BRCA1/BRCA2 variants We used targeted next-generation sequencing of a multigene panel, comprised of 94 cancer susceptibility genes (Illumina TruSight cancer panel) in order to assess the frequency of deleterious germline variants in this cohort.